These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27956420)

  • 1. Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.
    Valade E; Bouazza N; Lui G; Illamola SM; Benaboud S; Treluyer JM; Cobat A; Foissac F; De Sousa Mendes M; Chenevier-Gobeaux C; Suzan-Monti M; Rouzioux C; Assoumou L; Viard JP; Urien S; Ghosn J; Hirt D
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study.
    Valade E; Tréluyer JM; Illamola SM; Bouazza N; Foissac F; De Sousa Mendes M; Lui G; Chenevier-Gobeaux C; Suzan-Monti M; Rouzioux C; Assoumou L; Viard JP; Hirt D; Urien S; Ghosn J;
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6800-6. PubMed ID: 26282407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
    Dumond JB; Greene SA; Prince HMA; Chen J; Maas BM; Sykes C; Schauer AP; Blake KH; Nelson JAE; Gay CL; Kashuba ADM; Cohen MS
    Antivir Ther; 2019; 24(1):45-50. PubMed ID: 30375984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy.
    Kerr SJ; Punyawudho B; Thammajaruk N; Colbers A; Chaiyahong P; Phonphithak S; Sapsirisavat V; Ruxrungtham K; Burger DM; Avihingsanon A
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):368-74. PubMed ID: 25384393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics and viral activity of tenofovir in the male genital tract.
    Vourvahis M; Tappouni HL; Patterson KB; Chen YC; Rezk NL; Fiscus SA; Kearney BP; Rooney JF; Hui J; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2008 Mar; 47(3):329-33. PubMed ID: 18197124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
    Mallayasamy S; Chaturvedula A; Fossler MJ; Sale M; Goti V; Bumpus NN; Marzinke MA; Hendrix CW; Haberer JE;
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
    Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
    PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
    Lowe SH; van Leeuwen E; Droste JA; van der Veen F; Reiss P; Lange JM; Burger DM; Repping S; Prins JM
    Ther Drug Monit; 2007 Oct; 29(5):566-70. PubMed ID: 17898645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.
    Else LJ; Taylor S; Back DJ; Khoo SH
    Antivir Ther; 2011; 16(8):1149-67. PubMed ID: 22155899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
    Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
    Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
    Baheti G; King JR; Acosta EP; Fletcher CV
    AIDS; 2013 Jan; 27(2):221-5. PubMed ID: 23032419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
    Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
    Lê MP; Valantin MA; Assoumou L; Soulie C; Le Mestre S; Weiss L; Yazdanpanah Y; Molina JM; Bouchaud O; Raffi F; Reynes J; Calvez V; Marcelin AG; Costagliola D; Katlama C; Peytavin G;
    Pharmacotherapy; 2019 Apr; 39(4):514-520. PubMed ID: 30815916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elvitegravir concentrations in seminal plasma in HIV-1-infected men.
    Imaz A; Niubó J; Kashuba AD; Ferrer E; Sykes C; Rozas N; Acerete L; Vila A; Podzamczer D
    HIV Med; 2017 Mar; 18(3):225-230. PubMed ID: 27477062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
    Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
    Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
    Dumond JB; Nicol MR; Kendrick RN; Garonzik SM; Patterson KB; Cohen MS; Forrest A; Kashuba AD
    Clin Pharmacokinet; 2012 Dec; 51(12):809-22. PubMed ID: 23044523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
    Néant N; Gattacceca F; Lê MP; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
    Eur J Clin Pharmacol; 2018 Apr; 74(4):473-481. PubMed ID: 29374296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
    Jullien V; Tréluyer JM; Rey E; Jaffray P; Krivine A; Moachon L; Lillo-Le Louet A; Lescoat A; Dupin N; Salmon D; Pons G; Urien S
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3361-6. PubMed ID: 16048948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.
    Cottrell ML; Patterson KB; Prince HM; Jones A; White N; Wang R; Kashuba AD
    Antivir Ther; 2015; 20(8):795-803. PubMed ID: 26040011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
.
    Yamada E; Takagi R; Tanabe Y; Fujiwara H; Hasegawa N; Kato S
    Int J Clin Pharmacol Ther; 2017 Jul; 55(7):567-570. PubMed ID: 28427498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.